global messaging alerts
main content area

ApiJect Announces Molly Weaver, PhD, as New Chief Technology Officer

Stamford, CT, February 1, 2022 — ApiJect Systems, a medical technology public-benefit corporation, whose platform helps pharmaceutical and biotech companies efficiently fill-finish and deliver their injectable medicines in prefilled delivery systems, announced today the hiring of new Chief Technology Officer, Products, Molly Weaver, PhD.

Dr. Weaver is a seasoned industry leader whose background includes pharmaceutical and medical technology. Her leadership and expertise spans strategy, product development, and execution across a broad range of industrialization and drug delivery systems. This relevant experience has been applied in developing injectable technologies comprising self-injection devices and other injectable platforms, as well as to manage and launch products and commercialization of devices globally, including European and Asian markets.

She most recently served as Vice President for Containment Systems & Portfolio Management at West Pharmaceutical Services where she was responsible for elastomer and container R&D, product packaging and sterilization, and management of more than 30 projects across the full West portfolio of work, including partnership with commercial fill-finish operations. She previously worked at Becton Dickinson & Company and Unilife Medical Corporation. Dr. Weaver holds a Ph.D. in Mechanical Engineering Materials Science from Duke University and has published research in top journals in her field.

In her new role, Dr. Weaver will help facilitate ApiJect’s injectable platform development featuring BlowFill-Seal (BFS) technology and its initial product – a single-dose prefilled drug delivery system that is aseptically-filled, efficient to manufacture and can be produced in high volumes. This device is designed to allow a healthcare professional to twist a pen needle-style hub onto a BFS container holding an injectable medicine, creating a simple, scalable prefilled injector.

ApiJect Chief Executive Officer Jay Walker commented: “ApiJect has successfully built expertise and distributed capacity for its fill-finish platform. Recent partnerships, coupled with government and private investment, have demonstrated that ApiJect will play a critical role in reshoring the domestic supply chain of prefilled injectables and in creating global capacity. Molly’s deep expertise in pharmaceutical and medical technology product development and execution is a huge value-add for ApiJect at a time when our work finds itself at many intersections of pharma innovation. She is a leader that can communicate technically about a product in its design phase, during its regulatory review and when it reaches the assembly line floor. We are excited to welcome Molly to the ApiJect team.”

ApiJect Systems, Corp. is a public-benefit medical technology company working to bring prefilled, single-dose injections to more people in every market. The ApiJect Platform enables pharmaceutical and biotech companies to design scalable prefilled injectors and efficiently fill-finish them with their injectable drug products. This can be done either on one of their own ApiJect-licensed Blow-Fill-Seal packaging lines or at one of our world-class manufacturing partners. Learn more at or contact Steve Hofman at [email protected]

Social media & sharing icons powered by UltimatelySocial